Extending Urine Analysis By Direct Mass Spectrometry

Urinary Tract Infection (Diagnosis) Clinical Trial

Official title:

Clinical Study To Analyse The Influence Of An Extended Urine Analysis By Mass Spectrometry On Internal Medicine Wards At The University Hospital Of Basel

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02966977
• Other study ID #: 2016-01534
• Status: Completed
• Phase: N/A
• Start date: October 3, 2016
• Est. completion date: April 15, 2017

Study information

• Verified date: July 2020
• Source: University Hospital, Basel, Switzerland
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to evaluate the effect of an extension of conventional urine diagnostics with mass spectrometry in patients with a suspected UTI. Mass spectrometry is done directly from the urine sample (without an intermediate bacterial culture).The primary outcome is the time from the entry of a urine sample in the microbiological laboratory to the adequate/optimal/definitive treatment. Secondary outcomes are the time to diagnosis of a therapy relevant UTI, the quantity of antibiotics prescribed per patient and ward and a comparison of the length of hospital stay.

Description:

Urinary tract infections (UTI) have a high incidence rate and are one of the main reasons for initiating an antibiotic therapy, both, in the ambulatory and hospital setting. Mass spectrometry and improved sample preparation allows same-day identification of the causing agent of an UTI. This could shorten the time of suboptimal and potentially harmful empirical therapy. Additionally adverse effects from and the development of resistance against the applied antibiotic agent could be diminished. Matrix Assisted Laser Desorption Ionization (MALDI)— Time of Flight (TOF) Mass Spectrometry (MS) (MALDI-TOF MS) is already the preferred identification method in an increasing number of laboratories since it outperforms biochemical identification by speed and precision. This study tries to evaluate this new method to identify the causing agent of an UTI and evaluates its clinical implications.

This research project is a clinical trial that intends to analyse urine of patients with suspected urinary tract infections by mass spectrometry. This patient material is conventionally processed and not retrieved particularly for study purposes. Health-related personal data is collected from patients on the wards of the Clinic for Internal Medicine at the University Hospital Basel that have a urine sample analysed during the study period. No health-related personal data is particularly collected for this study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 192
• Est. completion date: April 15, 2017
• Est. primary completion date: March 31, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients of the Clinic for Internal Medicine at the University Hospital Basel with a suspected UTI and a minimum of one urine sample sent to the clinical microbiology laboratory.

Additionally at least one of the following:

• Patients consented to the general (i.e. "hospital-wide") use of their data and samples for research purposes.

• Patients consented to be enrolled in this study (by being informed about this study and signing the study specific consent form).

• Patients who are exempted from the need for a consent by way of an exception in agreement to the decisions of the competent ethics committee.

Exclusion Criteria:

• Minors or persons who declined the general use of their data and samples for research purposes (hospital wide consent) and declined or did not decide on the study specific consent form are not included.

Related Conditions & MeSH terms

• Infection
• Urinary Tract Infection (Diagnosis)
• Urinary Tract Infections

Intervention

Other:
• Conventional microbiological identification by culture plate
Conventional microbiological identification involves a step of overnight-2days growth of bacteria/fungi on culture plates prior to identification by biochemical methods or by mass spectrometry. See also information noted in arm/group description.
• Direct mass spectrometry identification from urine sample
The urine sample is concentrated and directly measured by a MALDI-TOF mass spectrometer without an intermediary microbiological culture on agar plates.

Locations

Country	Name	City	State
Switzerland	University Hospital Basel	Basel

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time from the entry of a urine sample in the microbiological laboratory to the adequate/optimal/definitive treatment.		1 week
Secondary	Time to diagnosis of a therapy relevant UTI.		1 week
Secondary	Quantity of antibiotics prescribed per patient and ward.		2 weeks
Secondary	Comparison of the length of hospital stay		2 weeks
Secondary	Comparison of the number of possible complications connected to UTI		4 weeks